High throughput screening of our compound library revealed a series of N-pyridyl-3-benzamides as low micromolar agonists of the human TRPV1 receptor. Synthesis of analogs in this series led to the discovery of a series of N-quinolin-3-yl-benzamides as low nanomolar antagonists of human TRPV1.
Johnson & Johnson Pharmaceutical Research and Development, Research and Early Development, Welsh and McKean Roads, Spring House, PA 19477, USA. michele137@comcast.net
